header
Image from OpenLibrary

Efficacy and safety of inhaled Salbutamol for the treatment of transient tachypnea of the newborn / Mohammed Ahmed Abdelazeem Mohammed ; Supervised Iman Ali Abdelaziz , Dina Hossam Eldine Hamed Elkhatib , Amira Mohamed Sabry

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mohammed Ahmed Abdelazeem Mohammed , 2017Description: 120 P. : charts , facsimiles ; 25cmOther title:
  • فعالية و سلامة استنشاق السالبيوتامول في علاج سرعة التنفس المؤقتة لدي حديثي الولادة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics Summary: Background : Postnatal respiratory complications among term infants are common. The most commonly reported cause of neonatal respiratory distress is transient tachypnea of the newborn with estimated incidence of 0.5% to 2.8% of all newborns.Objectives: The aim of this study was to evaluate the efficacy and safety of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn. Methods: It is randomized controlled clinical trial, on 50 neonates who will be admitted immediately or shortly after birth due to persistence of tachypnea to neonatal intensive care unit (NICU) of pediatric hospitals, Cairo University through the period from January 2016 till January 2017. Our study include 50 neonates (25 in the salbutamol group, 25 in the control group) with TTN born between 35 and 39 weeks of gestational age infants will be randomized in a blinded manner to receive one nebulized dose of salbutamol 0.15 mg/kg in 0.9% saline solution in addition to oxygen and IV fluids or received only oxygen and IV fluids.The response to inhaled salbutamol will be evaluated by determining respiratory rate, heart rate, clinical score of transient tachypnea of the newborn, level of respiratory support, before and at 30 minutes and 1 and 4 hours after drugs therapy. The duration and level of total respiratory support will be assigned along with the duration of hospitalization. Results: There is significant decrease in respiratory rate and TTN score in salbutamol group 4 hours after nebulized salbutamol.Comparing two groups after respiratory support, the total duration of oxygen treatment in hours and total duration of hospitalization in days are significantly shorter in salbutamol group than in control group. The time before initiating enteral feeding in hours is significantly shorter in salbutamol group than in control group.As regards safety of salbutamol, our study didn't show significant difference regarding heart rate and serum K before and 4 hours after nebulized salbutamol. Conclusion: Inhaled salbutamol treatment was effective in TTN without adverse events
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2017.Mo.E (Browse shelf(Opens below)) Not for loan 01010110073257000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2017.Mo.E (Browse shelf(Opens below)) 73257.CD Not for loan 01020110073257000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics

Background : Postnatal respiratory complications among term infants are common. The most commonly reported cause of neonatal respiratory distress is transient tachypnea of the newborn with estimated incidence of 0.5% to 2.8% of all newborns.Objectives: The aim of this study was to evaluate the efficacy and safety of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn. Methods: It is randomized controlled clinical trial, on 50 neonates who will be admitted immediately or shortly after birth due to persistence of tachypnea to neonatal intensive care unit (NICU) of pediatric hospitals, Cairo University through the period from January 2016 till January 2017. Our study include 50 neonates (25 in the salbutamol group, 25 in the control group) with TTN born between 35 and 39 weeks of gestational age infants will be randomized in a blinded manner to receive one nebulized dose of salbutamol 0.15 mg/kg in 0.9% saline solution in addition to oxygen and IV fluids or received only oxygen and IV fluids.The response to inhaled salbutamol will be evaluated by determining respiratory rate, heart rate, clinical score of transient tachypnea of the newborn, level of respiratory support, before and at 30 minutes and 1 and 4 hours after drugs therapy. The duration and level of total respiratory support will be assigned along with the duration of hospitalization. Results: There is significant decrease in respiratory rate and TTN score in salbutamol group 4 hours after nebulized salbutamol.Comparing two groups after respiratory support, the total duration of oxygen treatment in hours and total duration of hospitalization in days are significantly shorter in salbutamol group than in control group. The time before initiating enteral feeding in hours is significantly shorter in salbutamol group than in control group.As regards safety of salbutamol, our study didn't show significant difference regarding heart rate and serum K before and 4 hours after nebulized salbutamol. Conclusion: Inhaled salbutamol treatment was effective in TTN without adverse events

Issued also as CD

There are no comments on this title.

to post a comment.